首页> 美国卫生研究院文献>American Journal of Clinical and Experimental Immunology >Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province
【2h】

Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province

机译:安徽省系统性红斑狼疮患者HSP90B1基因多态性与糖皮质激素疗效及HRQoL的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective: The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic lupus erythematosus (SLE). Method: A total of 305 patients with SLE were recruited to the study. These patients were treated with GCs for 12 weeks and classified into two groups (sensitivity and insensitivity) according to the response to GCs measured by the scores on SLE disease activity index (SLEDAI). The HRQoL of SLE patients were evaluated by 36-item Short Form Health Survey (SF-36) at baseline and 12 weeks respectively. HapMap database and Haploview software were used to select HSP90B1 gene tag single nucleotide polymorphisms (SNPs). Benjamini & Hochberg (BH) method based on false discovery rate (FDR) was used for multiple testing correction. Results: A total of 291 patients were included in final data analysis with 14 patients excluded due to loss to follow-up. Among these patients, 160 patients were sensitive to GCs and 131 patients were insensitive to GCs. Twelve tag SNPs of HSP90B1 gene were selected. The rs12426382 polymorphism was associated with the efficacy of GCs (dominant model: crude OR=0.514, 95% CI=0.321-0.824, P=0.006; adjusted OR=0.513, 95% CI=0.317-0.831, P=0.007). After BH correction, there was no association between rs12426382 polymorphism and efficacy of GCs (PBH=0.084). In haplotype analysis, the haplotype CCCGAACATCCC (OR=2.273, 95% CI=1.248-4.139, P=0.006) and CTGGGACGTTC (OR=0.436, 95% CI=0.208-0.916, P=0.025) showed significant associations with the efficacy of GCs. After corrected by BH method, CCCGAACATCCC was still associated with the efficacy of GCs (PBH=0.048). The rs3794241, rs1165681, rs2722188, rs3794240 and rs10861147 polymorphisms were associated with the improvement of HRQoL among SLE patients (P < 0.05). But no association existed after the correction of BH method (P > 0.05). Conclusions: The results of this study demonstrated that HSP90B1 genetic polymorphisms might be associated with the efficacy of GCs, but not associated with the improvement of HRQoL in Anhui population with SLE.
机译:目的:本研究旨在探讨HSP90B1基因多态性与糖皮质激素(GCs)的疗效以及改善系统性红斑狼疮(SLE)患者健康相关生活质量(HRQoL)之间的关系。方法:共招募305例SLE患者。这些患者接受GC治疗12周,根据对SLE疾病活动指数(SLEDAI)评分所测得的对GC的反应,将其分为两组(敏感性和不敏感性)。 SLE患者的HRQoL分别在基线和12周时通过36项简短形式健康调查(SF-36)进行评估。使用HapMap数据库和Haploview软件选择HSP90B1基因标签单核苷酸多态性(SNP)。基于错误发现率(FDR)的Benjamini&Hochberg(BH)方法用于多次测试校正。结果:总共291例患者被纳入最终数据分析,其中14例患者因随访失败而被排除在外。在这些患者中,有160例对GC敏感,而131例对GC不敏感。选择了HSP90B1基因的十二个标签SNP。 rs12426382多态性与GC的功效有关(主要模型:粗OR = 0.514,95%CI = 0.321-0.824,P = 0.006;调整后的OR = 0.513,95%CI = 0.317-0.831,P = 0.007)。 BH校正后,rs12426382多态性与GC功效之间没有关联(PBH = 0.084)。在单倍型分析中,单倍型CCCGAACATCCC(OR = 2.273,95%CI = 1.248-4.139,P = 0.006)和CTGGGACGTTC(OR = 0.436,95%CI = 0.208-0.916,P = 0.025)显示出与GC。经BH法校正后,CCCGAACATCCC仍与GC的疗效相关( PBH = 0.048)。 rs3794241,rs1165681,rs2722188,rs3794240和rs10861147多态性与SLE患者HRQoL的改善有关( P <0.05)。但校正BH方法后没有关联( P 结论:该研究结果表明,HSP90B1基因多态性可能与GC的功效有关,但与SLE安徽人群的HRQoL改善无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号